ARID1A and clear cell adenocarcinoma: These cancers include aggressive subtypes, such as high-grade endometrioid carcinomas, serous carcinomas, and clear cell carcinomas, where ARID1A mutations contribute significantly to tumor progression, genomic instability, and treatment resistance [75].